Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DWPN | ISIN: US00444T2096 | Ticker-Symbol: R5XA
Frankfurt
01.11.24
08:00 Uhr
0,827 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TALPHERA INC Chart 1 Jahr
5-Tage-Chart
TALPHERA INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,8500,89013:05
0,8410,86601.11.

Aktuelle News zur TALPHERA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.10.Talphera verlängert Frist für Vereinbarung mit Nantahala Management10
01.10.Talphera extends agreement deadline with Nantahala Management1
01.10.TALPHERA, INC. - 8-K, Current Report1
03.09.Talphera CEO Vincent J. Angotti buys $7.6k in company stock5
19.08.Talphera starts key trial for anticoagulant nafamostat4
19.08.Talphera, Inc.: Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit117The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational trial in 166 patients at up to 14 clinical sites Primary endpoint in the NEPHRO CRRT study is measured...
► Artikel lesen
14.08.TALPHERA, INC. - S-8, Securities to be offered to employees in employee benefit plans1
14.08.TALPHERA, INC. - 8-K, Current Report1
14.08.Talphera, Inc.: Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update139NEPHRO CRRT study patient screening has initiated at multiple clinical sites The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational study in 166 patients at...
► Artikel lesen
24.06.TALPHERA, INC. - 8-K, Current Report1
20.05.Talphera, Inc.: Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)164SAN MATEO, Calif., May 20, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies...
► Artikel lesen
20.05.TALPHERA, INC. - S-8, Securities to be offered to employees in employee benefit plans1
15.05.Talphera Inc reports results for the quarter ended in March - Earnings Summary5
14.05.TALPHERA, INC. - 10-Q, Quarterly Report1
14.05.TALPHERA, INC. - 8-K, Current Report1
14.05.AcelRx Pharmaceuticals GAAP EPS of -$0.16 beats by $0.062
14.05.Talphera, Inc.: Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update279First patients at multiple sites are expected to be enrolled in the NEPHRO CRRT registrational study in Q2 2024 Dr. Shakil Aslam, an expert in renal diseases, including acute kidney injury, joins Talphera...
► Artikel lesen
13.05.AcelRx Pharmaceuticals Q1 2024 Earnings Preview2
06.03.Talphera, Inc.: Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update385Company rebranding and corporate transformation to Talphera completed in Q1 2024 First patient enrollment in the NEPHRO CRRT registrational study expected in Q1 2024 with a projected PMA submission...
► Artikel lesen
09.01.AcelRx Announces Rebranding With Name Change to Talphera, Inc.424Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on Nasdaq...
► Artikel lesen
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1